Chronic fatigue

Start here: not ordinary tiredness

Everyone knows tiredness that a rest or a weekend repairs. This is different. The fatigue of long COVID is a heavy, whole-body depletion that does not refill on schedule, so a normal day can leave you flattened and a small push can cost you days. People describe it as a dead battery, an empty tank, a body that will not answer.

Because the word fatigue sounds mild, the illness gets read as low motivation or poor fitness, which does real harm. The accurate frame is post-viral: a large share of people with this fatigue also meet the criteria for ME/CFS, a condition with decades of research behind it and a known tendency to worsen when patients are pushed to exercise.

It is measurable, not deconditioning

The claim that this is just being out of shape does not survive testing. Repeat exercise testing on two consecutive days shows that people with this illness often cannot reproduce their first-day performance, a drop in capacity that healthy unfit people do not show.¹

Muscle tells the same story. When researchers biopsied muscle before and after deliberately inducing a crash, the after sample looked worse, with local tissue damage and disturbed energy metabolism in the mitochondria.³ The problem lies in how the body makes and recovers energy, not in a fitness gap you can train away.

2-day exercise dropmuscle changes after exertionnot deconditioning

The overlap with post-exertional malaise

This fatigue rarely travels alone. Most people who have it also have post-exertional malaise, the delayed, outsized crash that follows physical, mental, or emotional effort by a day or more.²

That overlap is the key to managing it. The same effort that feels manageable in the moment is what buys the crash two days later, so the fatigue and the crash have to be handled together. Treating the fatigue as a call to do more, when it is really a signal to spend less, is how people spiral downward.

PEM overlap is the rulemanage fatigue and crashes together

Why pushing backfires

The historical advice for unexplained fatigue was graded exercise, a steady weekly increase in effort. For this illness that advice is not just unhelpful. Reviews of patient experience document a real risk of lasting deterioration when people are pushed to exercise through it.⁴

The harm signal is strong enough that the honest default is to treat steadily-escalating exercise as the wrong tool here. The goal is not to abandon movement but to stop using a strategy with a track record of making this specific problem worse, and to replace it with pacing that keeps you inside your energy limit.

graded exercise: harm documentedpushing can cause lasting declinepacing instead

The Epstein-Barr thread

Many people carry Epstein-Barr virus quietly for life. When the immune system is thrown off by COVID, that latent virus can reactivate, and studies of long COVID have linked EBV reactivation to ongoing fatigue.⁵

Whether the reactivation drives the fatigue or simply marks an immune system in disarray is not settled. It is a real and repeated association, not a proven cause, and it is one reason researchers are interested in the immune state behind this illness rather than the muscle alone.

association reportedmarker versus driver unresolved

The treatment marketplace, read carefully

No drug is approved for long COVID fatigue, which leaves a marketplace where claims outrun evidence. The clearest example is oxaloacetate, a supplement promoted for fatigue. Its positive reports come from open-label studies with no blinded placebo group and ties to the product's maker, the weakest design for a symptom that improves on its own in many people. A proper randomized trial is underway, and until it reports, enthusiasm is running ahead of proof.

Other agents are under study with thin or mixed evidence: low-dose naltrexone is being trialed, and an antidepressant, fluvoxamine, has shown mixed signals that are hard to separate from natural recovery. A more promising lead targets the mast-cell subset, since mast-cell activation is common in long COVID and some people improve on over-the-counter H1 and H2 antihistamines.⁶ Metformin, worth noting, helped prevent long COVID when given during the acute infection but has not shown benefit as a treatment for established fatigue.

oxaloacetate: industry-funded, open-labelLDN, fluvoxamine: thin or mixedantihistamine subset: emerging

What actually helps now

With no approved drug, the defensible plan treats the things that drag energy down and protects what you have. Pace to stay inside your energy limit so crashes do not compound, repair sleep, and manage any contributing problems such as orthostatic intolerance or a mast-cell-responsive pattern. For the antihistamine-responsive subset, a supervised trial of H1 and H2 blockers is low-risk and sometimes rewarded.

The honest expectation is management, not cure. Some people slowly regain capacity, others stay limited for long stretches, and the course is hard to predict. Steady pacing, realistic goals, and skepticism toward anything sold as a quick fix are the tools that consistently protect people while the science catches up.

pacing and substrate careantihistamine trial in the right subsetmanagement, not cure

What this means for you

If your fatigue does not lift with rest and gets worse when you push, the most important thing to know is that this is a recognized post-viral illness with a measurable biology, not a fitness problem or a failure of will. Two-day exercise testing and muscle studies show the body's energy system behaving abnormally. Naming it accurately changes how you and the people around you respond to it.

The practical core is short. Pace so that you spend below your limit and rest before you are forced to, because pushing through reliably costs more than it gains. Be wary of the supplement marketplace, especially products whose only evidence comes from studies run by the seller. Treat the fixable contributors, sleep, orthostatic symptoms, and a possible mast-cell pattern, and if a mast-cell pattern fits, a supervised trial of common antihistamines is low-risk. Expect to manage this rather than cure it, and hold realistic hope, since some people do slowly improve.

References

Each reference links to the source on PubMed, PMC, or the publisher.

1. Cardiopulmonary and metabolic responses during a 2-day CPET in ME/CFS: evidence of an abnormal second-day drop. 2024.
2. Post-exertional malaise among people with long COVID compared to ME/CFS. Work, 2023.
3. Muscle abnormalities worsen after post-exertional malaise in long COVID: biopsy evidence. Nature Communications, 2024.
4. Adverse outcomes in trials and surveys of graded exercise therapy for adults with post-viral fatigue. 2019.
5. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. 2023.
6. Mast cell activation symptoms are prevalent in long COVID. 2021.